Paolo Mulatero

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5019460/publications.pdf

Version: 2024-02-01

138 papers	10,698 citations	38742 50 h-index	32842 100 g-index
139 all docs	139 docs citations	139 times ranked	5533 citing authors

#	Article	IF	Citations
1	Primary aldosteronism in pregnancy. Reviews in Endocrine and Metabolic Disorders, 2023, 24, 39-48.	5.7	9
2	Response to Letter to the Editor from Rossi and Rossitto: â€œMineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronismâ€: Journal of Clinical Endocrinology and Metabolism, 2022, 107, e896-e897.	3.6	0
3	Supervised and unsupervised learning to define the cardiovascular risk of patients according to an extracellular vesicle molecular signature. Translational Research, 2022, , .	5.0	8
4	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 353-359.	2.2	9
5	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	3.6	127
6	Adrenal Venous Samplingâ€“Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1400-e1407.	3.6	25
7	Quality of life in primary aldosteronism: A prospective observational study. European Journal of Clinical Investigation, 2021, 51, e13419.	3.4	7
8	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. Frontiers in Pharmacology, 2021, 12, 668843.	3.5	0
9	BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. Hypertension, 2021, 77, 1647-1658.	2.7	8
10	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2021, 23, B77-B81.	0.1	4
11	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3655-e3664.	3.6	16
12	Clinical Score and Machine Learning-Based Model to Predict Diagnosis of Primary Aldosteronism in Arterial Hypertension. Hypertension, 2021, 78, 1595-1604.	2.7	10
13	Characterization of Circulating Extracellular Vesicle Surface Antigens in Patients With Primary Aldosteronism. Hypertension, 2021, 78, 726-737.	2.7	14
14	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	3.6	19
15	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1708-1716.	3.6	16
16	Diagnosis and treatment of primary aldosteronism. Lancet Diabetes and Endocrinology,the, 2021, 9, 876-892.	11.4	106
17	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertension Research, 2020, 43, 500-510.	2.7	26
18	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Annals of Surgery, 2020, 272, 1125-1132.	4.2	66

#	Article	IF	Citations
19	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e282-e289.	3.6	29
20	Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. Hypertension, 2020, 75, 163-172.	2.7	33
21	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. JAMA Network Open, 2020, 3, e2016209.	5.9	53
22	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2020, 22, H70-H73.	0.1	4
23	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
24	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1929-1936.	0.5	74
25	Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4382-e4392.	3.6	20
26	Age and Multimorbidity Predict Death Among COVID-19 Patients. Hypertension, 2020, 76, 366-372.	2.7	330
27	Primary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?. Hormone and Metabolic Research, 2020, 52, 366-372.	1.5	14
28	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3706-e3717.	3.6	47
29	Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. Hypertension, 2020, 75, 1025-1033.	2.7	60
30	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
31	The spectrum of low-renin hypertension. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101399.	4.7	17
32	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 105-108.	2.2	37
33	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology: Hypertension, 2020, 5, 100029.	2.2	69
34	Primary Aldosteronism in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2320-e2326.	3.6	12
35	Renal damage in primary aldosteronism. Journal of Hypertension, 2020, 38, 3-12.	0.5	63
36	Mutation affecting the conserved acidic WNK1 motif causes inherited hyperkalemic hyperchloremic acidosis. Journal of Clinical Investigation, 2020, 130, 6379-6394.	8.2	32

#	Article	IF	Citations
37	Prediction of hyperaldosteronism subtypes when adrenal vein sampling is unilaterally successful. European Journal of Endocrinology, 2020, 183, 657-667.	3.7	8
38	SUN-LB97 Targeted Metabolomics as a Screening Tool in the Diagnosis of Endocrine Hypertension. Journal of the Endocrine Society, 2020, 4, .	0.2	0
39	Primary Aldosteronism and Obstructive Sleep Apnea. Hypertension, 2019, 74, 1532-1540.	2.7	45
40	Characterization and Gene Expression Analysis of Serum-Derived Extracellular Vesicles in Primary Aldosteronism. Hypertension, 2019, 74, 359-367.	2.7	23
41	10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy. Journal of Hypertension, 2019, 37, 603-611.	0.5	14
42	Urinary Metabolic Signature of Primary Aldosteronism: Gender and Subtypeâ€Specific Alterations. Proteomics - Clinical Applications, 2019, 13, e1800049.	1.6	9
43	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 274-282.	2.5	28
44	Genetics of Familial Hyperaldosteronism. , 2019, , 623-630.		1
45	Primary aldosteronism in the primary care setting. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 155-159.	2.3	12
46	GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism. European Journal of Endocrinology, 2018, 178, R101-R111.	3.7	46
47	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
48	Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2018, 6, 41-50.	11.4	582
49	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. Journal of Pharmacological and Toxicological Methods, 2018, 94, 29-35.	0.7	6
50	The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. Endocrine Reviews, 2018, 39, 1057-1088.	20.1	168
51	Diagnostic approach to lowâ€renin hypertension. Clinical Endocrinology, 2018, 89, 385-396.	2.4	32
52	Liddle Syndrome: Review of the Literature and Description of a New Case. International Journal of Molecular Sciences, 2018, 19, 812.	4.1	69
53	Role of Cryptochrome-1 and Cryptochrome-2 in Aldosterone-Producing Adenomas and Adrenocortical Cells. International Journal of Molecular Sciences, 2018, 19, 1675.	4.1	5
54	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	2.7	51

#	Article	IF	Citations
55	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	2.7	94
56	Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. Endocrine, 2017, 58, 503-512.	2.3	22
57	UHPLCâ€“MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 279-285.	2.8	33
58	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
59	Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in PrimaryÂCareÂPractice. Journal of the American College of Cardiology, 2017, 69, 1811-1820.	2.8	520
60	Mouse Models of Primary Aldosteronism: From Physiology to Pathophysiology. Endocrinology, 2017, 158, 4129-4138.	2.8	24
61	The SPARTACUS Trial: Controversies and Unresolved Issues. Hormone and Metabolic Research, 2017, 49, 936-942.	1.5	33
62	Is Primary Aldosteronism Still Largely Unrecognized?. Hormone and Metabolic Research, 2017, 49, 908-914.	1.5	50
63	A Case of Adrenal Vein Sampling in Primary Aldosteronism With Homolateral Suppression. Journal of the Endocrine Society, 2017, 1, 401-406.	0.2	3
64	Is There a Role for Genomics in the Management of Hypertension?. International Journal of Molecular Sciences, 2017, 18, 1131.	4.1	40
65	Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?. International Journal of Molecular Sciences, 2017, 18, 848.	4.1	40
66	Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. Journal of Hypertension, 2016, 34, 920-927.	0.5	61
67	Guidelines for primary aldosteronism. Journal of Hypertension, 2016, 34, 2253-2257.	0.5	134
68	Hyperaldosteronism: How to Discriminate Among Different Disease Forms?. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 203-208.	2.2	3
69	UHPLCâ€“MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. Journal of Pharmaceutical and Biomedical Analysis, 2016, 129, 535-541.	2.8	39
70	Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism. Endocrine, 2016, 54, 826-829.	2.3	2
71	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. Hypertension, 2016, 67, e3-4.	2.7	1
72	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2016, 67, 146-152.	2.7	63

#	Article	IF	Citations
73	Issues in the Diagnosis and Treatment of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 73-82.	2.2	0
74	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension, 2015, 66, 248-253.	2.7	10
75	Aldosterone effects on glomerular structure and function. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 730-738.	1.7	20
76	A Case of Severe Hyperaldosteronism Caused by a De Novo Mutation Affecting a Critical Salt Bridge Kir3.4 Residue. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E114-E118.	3.6	53
77	Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Molecular and Cellular Endocrinology, 2015, 411, 146-154.	3.2	115
78	KCNJ5 Mutations Are the Most Frequent Genetic Alteration in Primary Aldosteronism. Hypertension, 2015, 65, 507-509.	2.7	34
79	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1262-E1269.	3.6	4
80	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes and Endocrinology,the, 2015, 3, 296-303.	11.4	134
81	Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Molecular and Cellular Endocrinology, 2015, 399, 311-320.	3.2	45
82	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	2.7	248
83	Aldosterone Suppression on Contralateral Adrenal During Adrenal Vein Sampling Does Not Predict Blood Pressure Response After Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4158-4166.	3.6	62
84	Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. Pharmacogenomics, 2014, 15, 1643-1652.	1.3	27
85	Somatic ATP1A1 , ATP2B3 , and KCNJ5 Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	2.7	151
86	1Î±,25-Dihydroxyvitamin D3 inhibits the human H295R cell proliferation by cell cycle arrest: A model for a protective role of vitamin D receptor against adrenocortical cancer. Journal of Steroid Biochemistry and Molecular Biology, 2014, 140, 26-33.	2.5	26
87	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Molecular and Cellular Endocrinology, 2014, 394, 13-20.	3.2	48
88	A Novel Y152C KCNJ5 Mutation Responsible for Familial Hyperaldosteronism Type III. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1861-E1865.	3.6	86
89	Role of KCNJ5 in familial and sporadic primary aldosteronism. Nature Reviews Endocrinology, 2013, 9, 104-112.	9.6	101
90	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics, 2013, 45, 440-444.	21.4	460

#	Article	IF	Citations
91	Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4826-4833.	3.6	348
92	Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism. Current Hypertension Reviews, 2013, 9, 156-165.	0.9	9
93	KCNJ5 Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. Hypertension, 2012, 59, 235-240.	2.7	176
94	Visinin-Like 1 Is Upregulated in Aldosterone-Producing Adenomas With KCNJ5 Mutations and Protects From Calcium-Induced Apoptosis. Hypertension, 2012, 59, 833-839.	2.7	64
95	18-Hydroxycorticosterone, 18-Hydroxycortisol, and 18-Oxocortisol in the Diagnosis of Primary Aldosteronism and Its Subtypes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 881-889.	3.6	105
96	Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2012, 59, 840-846.	2.7	87
97	Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. Endocrine Journal, 2012, 59, 497-502.	1.6	24
98	Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
99	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Molecular and Cellular Endocrinology, 2012, 355, 162-168.	3.2	18
100	Concurrent primary aldosteronism and subclinical cortisol hypersecretion. Journal of Hypertension, 2011, 29, 1773-1777.	0.5	50
101	Diagnosis and treatment of primary aldosteronism. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 3-9.	5.7	30
102	Is Familial Hyperaldosteronism Underdiagnosed in Hypertensive Children?. Hypertension, 2011, 57, 1053-1055.	2.7	15
103	Psychological Assessment of Primary Aldosteronism: A Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E878-E883.	3.6	91
104	Prevalence and Characteristics of Familial Hyperaldosteronism. Hypertension, 2011, 58, 797-803.	2.7	128
105	Evaluation of primary aldosteronism. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 188-193.	2.3	21
106	Teratocarcinoma-Derived Growth Factor-1 Is Upregulated in Aldosterone-Producing Adenomas and Increases Aldosterone Secretion and Inhibits Apoptosis In Vitro. Hypertension, 2010, 55, 1468-1475.	2.7	43
107	Impact of Different Diagnostic Criteria During Adrenal Vein Sampling on Reproducibility of Subtype Diagnosis in Patients With Primary Aldosteronism. Hypertension, 2010, 55, 667-673.	2.7	140
108	Differential diagnosis of primary aldosteronism subtypes. Current Hypertension Reports, 2009, 11, 217-223.	3.5	46

#	Article	IF	Citations
109	Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 121-125.	2.2	2
110	Roles of Clinical Criteria, Computed Tomography Scan, and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1366-1371.	3.6	149
111	Aldosterone as an Independent Factor in Cerebrovascular Damage. Clinical and Experimental Hypertension, 2008, 30, 785-797.	1.3	6
112	Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. Journal of Hypertension, 2008, 26, 1577-1582.	0.5	82
113	Captopril Test Can Give Misleading Results in Patients With Suspect Primary Aldosteronism. Hypertension, 2007, 50, e26-7.	2.7	55
114	Rapid Cortisol Assay during Adrenal Vein Sampling in Patients with Primary Aldosteronism. Clinical Chemistry, 2007, 53, 1968-1971.	3.2	95
115	Diagnosis and treatment of low-renin hypertension. Clinical Endocrinology, 2007, 67, 324-334.	2.4	89
116	Controversies on the Diagnosis of Primary Aldosteronism. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 173-178.	2.2	0
117	Comparison of Confirmatory Tests for the Diagnosis of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2618-2623.	3.6	174
118	Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2006, 4, 75-91.	1.0	40
119	QT interval in patients with primary aldosteronism and low-renin essential hypertension. Journal of Hypertension, 2006, 24, 2459-2464.	0.5	25
120	Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 454-459.	3.6	340
121	Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney International, 2005, 67, 631-637.	5.2	33
122	The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108.	2.2	0
123	Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism, 2005, 16, 114-119.	7.1	125
124	Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1045-1050.	3.6	862
125	Genetics of primary aldosteronism. Journal of Hypertension, 2004, 22, 663-670.	0.5	28
126	Drug Effects on Aldosterone/Plasma Renin Activity Ratio in Primary Aldosteronism. Hypertension, 2002, 40, 897-902.	2.7	346

#	Article	IF	Citations
127	Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3187-3191.	3.6	67
128	Hypertension, genotype and oral contraceptives. Pharmacogenomics, 2002, 3, 57-63.	1.3	6
129	Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B₂Receptor and Î±-Adducin Gene Polymorphisms. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3337-3343.	3.6	30
130	A time-resolved fluoroimmunoassay for 18-oxocortisol and 18-hydroxycortisol. Journal of Steroid Biochemistry and Molecular Biology, 2002, 82, 83-88.	2.5	19
131	Glucocorticoid Remediable Aldosteronism: Low Morbidity and Mortality in a Four-Generation Italian Pedigree. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3187-3191.	3.6	14
132	Deletion Hybrid Genes, due to Unequal Crossing Over betweenCYP11B1(11Î²-Hydroxylase) andCYP11B2(Aldosterone Synthase) Cause Steroid 11Î²-Hydroxylase Deficiency and Congenital Adrenal Hyperplasia¹. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3197-3201.	3.6	38
133	CYP11B2Gene Polymorphisms in Idiopathic Hyperaldosteronism. Hypertension, 2000, 35, 694-698.	2.7	72
134	Î± ₁ -Adrenergic Receptor Subtypes in Human Peripheral Blood Lymphocytes. Hypertension, 1999, 33, 708-712.	2.7	46
135	Ca2+ channels of the L-type in peripheral blood lymphocytes of essential hypertensives. American Journal of Hypertension, 1999, 12, 40-46.	2.0	1
136	Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2573-2575.	3.6	121
137	Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. Liver, 1998, 18, 420-426.	0.1	15
138	The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nature Structural and Molecular Biology, 1997, 4, 32-35.	8.2	88